Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Regencell Bioscience Holdings Ltd (RGC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: RGC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 857.05% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.60B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.62 | 52 Weeks Range 0.08 - 83.60 | Updated Date 06/29/2025 |
52 Weeks Range 0.08 - 83.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date 2025-06-30 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.11% | Return on Equity (TTM) -43.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8536892836 | Price to Sales(TTM) - |
Enterprise Value 8536892836 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -44.58 | Shares Outstanding 494488992 | Shares Floating 29901744 |
Shares Outstanding 494488992 | Shares Floating 29901744 | ||
Percent Insiders 93.84 | Percent Institutions 0.07 |
Upturn AI SWOT
Regencell Bioscience Holdings Ltd
Company Overview
History and Background
Regencell Bioscience Holdings Ltd. was founded in 2019 and is a biotechnology company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and diseases.
Core Business Areas
- Research and Development: Focuses on researching and developing TCM formulations for neurocognitive disorders, including Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD).
- Commercialization: Aims to commercialize its TCM formulations through clinical trials and eventual market entry.
Leadership and Structure
The leadership team consists of CEO Yat-Gai Au, CFO Eliza Wong, and other key personnel. The company structure is a typical biotechnology setup, focusing on research, clinical trials, and regulatory approvals.
Top Products and Market Share
Key Offerings
- RGC-COV19: A TCM formula designed to treat COVID-19. Market share data is unavailable due to the product being in development. Competitors in COVID-19 treatment include pharmaceutical giants with vaccines and antiviral medications.
- Autim Serum: A TCM formula designed to treat Autism Spectrum Disorder. Market share data is unavailable due to the product being in development. Competitors include therapies and medication to manage autism symptoms.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investments in research and development. It is closely regulated by agencies like the FDA. The TCM market is growing globally, especially in Asia.
Positioning
Regencell is a relatively small player in the biotechnology industry. It differentiates itself by focusing on TCM and neurocognitive disorders, but faces competition from larger, more established pharmaceutical companies.
Total Addressable Market (TAM)
The global autism spectrum disorder (ASD) market size was valued at USD 2.73 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2030. Regencell aims to capture a portion of this TAM with its Autim Serum, but faces significant competition and developmental hurdles.
Upturn SWOT Analysis
Strengths
- Focus on Traditional Chinese Medicine
- Proprietary formulations
- Potential market for neurocognitive disorder treatments
- Experienced leadership team with pharmaceutical and TCM knowledge
Weaknesses
- Limited operating history
- Dependence on successful clinical trials
- High research and development costs
- Small market capitalization
Opportunities
- Growing global interest in TCM
- Potential for partnerships with larger pharmaceutical companies
- Expansion into new markets
- Successful clinical trial outcomes
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Adverse side effects from TCM treatments
Competitors and Market Share
Key Competitors
- Roche Holding AG (RHHBY)
- Novartis AG (NVS)
- Johnson & Johnson (JNJ)
Competitive Landscape
Regencell faces significant competition from larger pharmaceutical companies with more resources and established market presence. Regencell's competitive advantage lies in its focus on TCM, but this is unproven.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's young age.
Future Projections: Future growth is highly dependent on successful clinical trials and regulatory approvals. Analyst estimates are not readily available.
Recent Initiatives: Focus on clinical trials for Autim Serum and RGC-COV19, as well as expansion in regulatory approvals.
Summary
Regencell Bioscience Holdings Ltd. is a small biotechnology company with a focus on TCM for neurocognitive disorders. The company's future is highly dependent on the success of its clinical trials and regulatory approvals. The company has many large and well-established competitors. Regencell must find more effective strategies to gain more market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. This analysis is based on publicly available information and may not be completely accurate or up-to-date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regencell Bioscience Holdings Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-16 | Founder, Chairman & CEO Mr. Yat-Gai Au | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 12 | |
Full time employees 12 | |||
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.